Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a Healthcare company (Biotechnology) with a market capitalization of $4.5B. The Maz Rating grades it against the other companies in its sector.
Ionis Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.96, Ionis Pharmaceuticals, Inc. trades at 4.9x sales and 11.8x book value. Over the last twelve months it generated about $924M of revenue and a net loss of $532M. It runs a gross margin of 98.2%, an operating margin of -58.9% and a net margin of -56.9%. It shows return on equity of -120.4%, return on invested capital of -21.6% and a free cash flow yield of -13.2%. On the balance sheet: a debt-to-equity ratio of 5.47 and a current ratio of 5.43. Over the past 52 weeks the share price ranged from $26.55 to $86.74, with a beta of 0.40.
Ionis Pharmaceuticals, Inc. does not currently pay a dividend.
33 Wall Street analyst ratings cover the stock: 1 Strong Buy, 20 Buy and 12 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.